Pharmaceutical company Lupin Ltd has got the final approval for Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to sell generic version of ViiV Healthcare’s (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg. These tablets are prescribed in the treatment of HIV.
In a filing with the stock exchanges, Lupin said that its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg/ 300 mg are used in combination with other antiretrovirals or alone for the treatment of HIV1 infection. The company said that it was the first to file an ANDA for Trizivir Tablets and would be entitled to 180 days of exclusive marketing.
These tablets had annual US sales of around $111.6 million, the statement said.
Lupin shares are trading at Rs 864.70, up by Rs 11.80, on the NSE.